Annovis Bio secures U.S. patent for treatment of acute TBI with buntanetap

Annovis Bio announced the issuance of a U.S. patent for methods of treating acute traumatic brain injuries, TBI, with its lead drug candidate, buntanetap. “We are thrilled to achieve this significant milestone for buntanetap,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. “Nerve cell death is a common underlying factor in many brain conditions, beyond just Alzheimer’s and Parkinson’s. Our preclinical studies in TBI and stroke animal models have demonstrated buntanetap’s efficacy in preventing cell death and loss of function, and it is our duty to explore its potential benefits for victims of brain trauma, a prevalent issue in the U.S.”